Follow
Jinsy Andrews, MD, MSc
Jinsy Andrews, MD, MSc
Verified email at cumc.columbia.edu - Homepage
Title
Cited by
Cited by
Year
Trial of Antisense Oligonucleotide Tofersen for SOD1 ALS
TM Miller, ME Cudkowicz, A Genge, PJ Shaw, G Sobue, RC Bucelli, ...
New England Journal of Medicine 387 (12), 1099-1110, 2022
2642022
Study of 962 patients indicates progressive muscular atrophy is a form of ALS
WK Kim, X Liu, J Sandner, M Pasmantier, J Andrews, LP Rowland, ...
Neurology 73 (20), 1686-1692, 2009
2372009
Revised Airlie House consensus guidelines for design and implementation of ALS clinical trials
LH Van Den Berg, E Sorenson, G Gronseth, EA Macklin, J Andrews, ...
Neurology 92 (14), e1610-e1623, 2019
1312019
Real-world evidence of riluzole effectiveness in treating amyotrophic lateral sclerosis
JA Andrews, CE Jackson, TD Heiman-Patterson, P Bettica, BR Brooks, ...
Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration 21 (7-8), 509-518, 2020
1062020
Cognitive-behavioral screening reveals prevalent impairment in a large multicenter ALS cohort
J Murphy, P Factor-Litvak, R Goetz, C Lomen-Hoerth, PL Nagy, J Hupf, ...
Neurology 86 (9), 813-820, 2016
982016
CK‐2127107 amplifies skeletal muscle response to nerve activation in humans
JA Andrews, TM Miller, V Vijayakumar, R Stoltz, JK James, L Meng, ...
Muscle & Nerve 57 (5), 729-734, 2018
802018
Body mass index (BMI) as predictor of ALSFRS-R score decline in ALS patients
R Reich-Slotky, J Andrews, B Cheng, R Buchsbaum, D Levy, P Kaufmann, ...
Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration 14 (3), 212-216, 2013
752013
Association between decline in slow vital capacity and respiratory insufficiency, use of assisted ventilation, tracheostomy, or death in patients with amyotrophic lateral sclerosis
JA Andrews, L Meng, SF Kulke, SA Rudnicki, AA Wolff, ME Bozik, FI Malik, ...
JAMA neurology 75 (1), 58-64, 2018
712018
Amyotrophic lateral sclerosis: Update on clinical management
SP Norris, MFN Likanje, JA Andrews
Current opinion in neurology 33 (5), 641-648, 2020
672020
Respiratory measures in amyotrophic lateral sclerosis
N Lechtzin, ME Cudkowicz, M de Carvalho, A Genge, O Hardiman, ...
Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration 19 (5-6), 321-330, 2018
632018
Design of a randomized, placebo-controlled, phase 3 trial of tofersen initiated in clinically presymptomatic SOD1 variant carriers: the ATLAS study
M Benatar, J Wuu, PM Andersen, RC Bucelli, JA Andrews, M Otto, ...
Neurotherapeutics 19 (4), 1248-1258, 2022
602022
Experience with the Awaji Island modifications to the ALS diagnostic criteria
A Chen, L Weimer, T Brannagan III, M Colin, J Andrews, H Mitsumoto, ...
Muscle & nerve 42 (5), 831-832, 2010
602010
Amyotrophic lateral sclerosis: clinical management and research update
J Andrews
Current neurology and neuroscience reports 9 (1), 59-68, 2009
572009
Adaptive platform trials to transform amyotrophic lateral sclerosis therapy development
S Paganoni, JD Berry, M Quintana, E Macklin, BR Saville, MA Detry, ...
Annals of neurology 91 (2), 165-175, 2022
492022
A Phase 2, Double-Blind, Randomized, Dose-Ranging Trial Of Reldesemtiv In Patients With ALS
JM Shefner, JA Andrews, A Genge, C Jackson, N Lechtzin, TM Miller, ...
Amyotrophic lateral sclerosis and frontotemporal degeneration 22 (3-4), 287-299, 2021
492021
A phase III trial of tirasemtiv as a potential treatment for amyotrophic lateral sclerosis
JM Shefner, ME Cudkowicz, O Hardiman, BM Cockroft, JH Lee, FI Malik, ...
Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration 20 (7-8), 584-594, 2019
482019
Reldesemtiv in patients with spinal muscular atrophy: a phase 2 hypothesis-generating study
SA Rudnicki, JA Andrews, T Duong, BM Cockroft, FI Malik, L Meng, J Wei, ...
Neurotherapeutics 18 (2), 1127-1136, 2021
462021
Amyotrophic lateral sclerosis care and research in the United States during the COVID‐19 pandemic: Challenges and opportunities
JA Andrews, JD Berry, RH Baloh, N Carberry, ME Cudkowicz, B Dedi, ...
Muscle & nerve 62 (2), 182-186, 2020
452020
ALS Multicenter Cohort Study of Oxidative Stress (ALS COSMOS): study methodology, recruitment, and baseline demographic and disease characteristics
H Mitsumoto, P Factor-Litvak, H Andrews, RR Goetz, L Andrews, ...
Amyotrophic lateral sclerosis and frontotemporal degeneration 15 (3-4), 192-203, 2014
432014
A randomized, placebo-controlled, double-blind phase IIb trial evaluating the safety and efficacy of tirasemtiv in patients with amyotrophic lateral sclerosis
JM Shefner, AA Wolff, L Meng, A Bian, J Lee, D Barragan, JA Andrews, ...
Amyotrophic lateral sclerosis and frontotemporal degeneration 17 (5-6), 426-435, 2016
412016
The system can't perform the operation now. Try again later.
Articles 1–20